Compare Amphastar Pharmaceuticals Inc (AMPH) vs Lucid Group Inc (LCID) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Lucid Group (LCID) trades at $5.55, down 4.8% on the day, reflecting persistent bearish technical signals and fundamental challenges. The company continues to report significant losses, with a net income margin of -239.81% and negative cash flow from operations of $2.93B in 2025. Recent news highlights shareholder dilution concerns and multiple class-action lawsuits, adding to investor uncertainty.

The outlook remains highly speculative with substantial execution and liquidity risks, though a consensus analyst price target of $11.75 suggests potential upside if the company can achieve scale and improve profitability. High cash burn and competitive pressures in the EV market present significant headwinds for near-term performance.